Boston Scientific (BSX) 8-K/A Regulation FD Disclosure

Where are we going? Guidance 2015E Goals 2016E Goals 2017E Goals 2018-2019E Organic Revenue +3-5% +3-6% +3-6% +4-7% Operational Revenue +5-8% with AMS & Bayer Int. +5-9% with AMS Upside from potential M&A Adjusted Op. Margin 22.0-22.5% +~150 bps 25%+ +50-100bps annually Adjusted EPS $0.88-0.92 +5%-10% +13%-17% ex FX target double digit growth ex-FX Mid-single digit growth company with differentiated margin expansion, driving double-digit adjusted EPS growth (excluding FX) 22 Exhibit 99.1

2015 Guidance: Continued execution Measure FY 2015 As Reported Revenue ($M) 7,225 to 7,375 Operational Growth +4% to +6% As Reported Growth -2% to flat vs. FY 2014A Adjusted Gross Margin 71% to 72% +30 bps to +130 bps Adjusted SG&A % of Sales 36.5% to 37.5% -140 bps to -40 bps Adjusted R&D % of Sales 11% to 12% -10 bps to +90 bps Adjusted Operating Margin 22.0% to 22.5% +180 bps to +230 bps Adjusted Tax Rate 13% to 15% Adjusted EPS $0.88 to $0.92 GAAP EPS $0.32 to $0.38 133 Exhibit 99.1

Where are we going? Guidance 2015E Goals 2016E Goals 2017E Goals 2018-2019E Organic Revenue +3-5% +3-6% +3-6% +4-7% Operational Revenue +5-8% with AMS & Bayer Int. +5-9% with AMS Upside from potential M&A Adjusted Op. Margin 22.0-22.5% +~150 bps 25%+ +50-100bps annually Adjusted EPS $0.88-0.92 +5%-10% +13%-17% ex FX target double digit growth ex-FX Mid-single digit growth company with differentiated margin expansion, driving double-digit adjusted EPS growth (excluding FX) 143 Exhibit 99.1